Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Status:
Withdrawn
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Patients will be tested for mutations in the BRCA2 gene. If they have a BRCA2 mutation, they
will be treated with Mitomycin-C as described here. The patients with an identified gene
mutation will also be provided with genetic counseling.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins